SLC5A2 and hydrops fetalis: This review aims to elucidate the potential sex-related differences in treatment efficacy for the cornerstone medications used in the management of HF: β-blockers, renin-angiotensin-system inhibitors (RASi), mineralocorticoid receptor antagonists (MRA), and sodium glucose co-transporter 2 (SGLT2) inhibitors.